Lux Capital

Frontera Health is changing autism care in underprivileged regions with AI-powered tools that assist physicians in evaluating and treating children with autism and related diseases.

Atrandi Biosciences is a biotechnology company focusing on next-generation single-cell technology, specifically single-cell eukaryotic DNA sequencing. This innovative approach enables the analysis of genomic alterations and cellular heterogeneity.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

JOYA is the first employee skincare and wellness benefit platform. The company's goal is to provide tailored access to services such as skin cancer screenings, skin condition treatment, anti-aging, acne, and hair loss care from reputable physicians at an accessible cost.

Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Atavistik Bio is a pre-clinical biotechnology company dedicated to discovering and developing novel therapies for metabolic diseases and cancer. The company specializes in identifying metabolite-protein interactions and leveraging nature's allosteric control mechanisms to create innovative drug candidates. By focusing on genetically validated targets, Atavistik Bio aims to pioneer first-in-class treatments that harness these unique biological processes, positioning itself at the forefront of biopharmaceutical advancements.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Siren Biotechnology is a biotechnology company focused on cancer treatment through an integrated therapeutic modality that combines adeno-associated virus–based gene therapy with cytokine immunotherapy. The approach delivers targeted cytokines to tumors, aiming to activate both innate and adaptive immune responses while addressing toxicity and off-target effects. By uniting gene delivery with immunotherapy in a single modality, the company seeks to enhance tumor cell elimination and improve long-term anti-tumor immunity, potentially reducing recurrence in cancer patients.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

Fertilidad Integral is a fertility care provider focused on comprehensive treatments, including egg freezing, embryo freezing, in vitro fertilization, and intrauterine insemination. The company emphasizes patient-centered care with a focus on wellness and emotional support, offering therapy sessions with a specialist to accompany patients through their fertility journey. It combines clinical precision with compassionate, personalized guidance to help individuals and couples pursue family-building goals.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

WellTheory operates a virtual care platform specializing in autoimmune and inflammatory conditions. It combines community support, dietary adjustments, lifestyle changes, and personalized insights to provide evidence-based recommendations for managing these conditions.

Plexium, Inc. is a biotechnology company based in San Diego, California, specializing in the development of targeted protein degradation therapeutics aimed at treating cancer and neurodegenerative diseases. Founded in 2017, Plexium focuses on identifying E3 ligase modulating small molecules to create innovative therapies. The company has developed a screening platform known as DELPhe, which utilizes advanced techniques to miniaturize cell-based assays for high-content readouts. This platform enables the modulation of E3 ligases to selectively target various cancers, including small cell lung and breast tumors, while also inducing immune responses. By exploring next-generation drug candidates that extend beyond traditional approaches, Plexium is poised to uncover new therapeutic possibilities across a wide range of medical applications.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Gandeeva Therapeutics is a precision biotechnology company that combines cryogenic electron microscopy (cryo-EM) and machine learning to discover and develop therapeutics by targeting and modulating key protein-protein interactions. Its structure-guided drug discovery platform comprises SPOTLIGHT for target prediction and validation, HYPERFOCUS for hit identification from virtual and fragment libraries, and CRYO-CADD for lead optimization. The company pursues a preclinical oncology program focused on difficult-to-treat cancers with novel protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area of Canada, Gandeeva aims to advance differentiated therapeutics and improve outcomes for patients by leveraging its integrated imaging, modeling, and screening capabilities.

Gameto is a biotechnology company focused on advancing female reproductive health through innovative therapies. Recognizing the significant lack of treatment options in this underserved area, Gameto employs cutting-edge scientific techniques to develop solutions that enhance the quality of life for women. The company utilizes cellular engineering to create a platform that produces engineered ovarian and endometrial cell lines capable of mimicking the functions of natural cells, including hormone production and response. This platform underpins a portfolio of cellular therapeutics aimed at addressing various female reproductive diseases. Gameto's first initiative, Fertilo, targets improvements in in vitro fertilization (IVF) and egg freezing processes, striving to make them shorter, safer, and more effective. Additionally, the company is developing Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy designed to mitigate health issues related to primary ovarian insufficiency and menopause. Through these efforts, Gameto aims to transform the landscape of female reproductive health care.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

AllStripes is a healthcare technology company focused on accelerating the development of new treatments for rare diseases. The company has created a platform that enables the generation of regulatory-ready evidence, facilitating rare disease research and drug development. AllStripes operates a two-sided network that connects patients with rare diseases and advocacy groups to life science companies seeking new drug candidates. Through this network, patients can contribute their medical data and participate in treatment research online, while life science companies gain access to valuable data and insights to support their drug development efforts.

Atavistik Bio is a pre-clinical biotechnology company dedicated to discovering and developing novel therapies for metabolic diseases and cancer. The company specializes in identifying metabolite-protein interactions and leveraging nature's allosteric control mechanisms to create innovative drug candidates. By focusing on genetically validated targets, Atavistik Bio aims to pioneer first-in-class treatments that harness these unique biological processes, positioning itself at the forefront of biopharmaceutical advancements.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Multiply Labs develops robotic-enabled manufacturing for personalized pharmaceutical capsules, combining pharmaceutical science with robotics to produce tailor-made capsules that align with individual patient metabolic needs. The company operates a robotic manufacturing facility and has introduced 3D-printed capsules, aiming to address scaling challenges in biotech and improve the efficiency and cost of producing patient-specific medicines.

SteadyMD, Inc. is a provider of online primary care services based in St. Louis, Missouri, with an additional office in Westlake Village, California. Founded in 2016, the company connects patients with board-certified clinicians through a digital platform that facilitates telehealth services for various medical conditions, dietary preferences, and lifestyle choices. Patients can communicate with their doctors via text, call, or video chat, allowing for personalized and comprehensive care. SteadyMD also serves as a telehealth infrastructure provider, enabling healthcare leaders to scale their telehealth offerings across all 50 states by providing a licensed clinician workforce and support in clinical operations, legal, and regulatory matters. The company's innovative approach aims to improve access to high-quality care by addressing the complexities of chronic illnesses and ensuring that patients receive adequate time and attention from their healthcare providers.

DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in the development of an innovative artificial intelligence-powered magnetic resonance imaging (MRI) system. The company's technology aims to significantly reduce the cost, size, and weight of traditional MRI machines, thereby enhancing accessibility to medical imaging for patients worldwide. By utilizing generative topological design for its hardware and deep learning techniques for image processing, DeepSpin's MRI system seeks to make advanced medical imaging available in a variety of previously underserved healthcare settings. This approach not only aims to improve patient care but also to democratize access to essential medical diagnostics globally.

Plexium, Inc. is a biotechnology company based in San Diego, California, specializing in the development of targeted protein degradation therapeutics aimed at treating cancer and neurodegenerative diseases. Founded in 2017, Plexium focuses on identifying E3 ligase modulating small molecules to create innovative therapies. The company has developed a screening platform known as DELPhe, which utilizes advanced techniques to miniaturize cell-based assays for high-content readouts. This platform enables the modulation of E3 ligases to selectively target various cancers, including small cell lung and breast tumors, while also inducing immune responses. By exploring next-generation drug candidates that extend beyond traditional approaches, Plexium is poised to uncover new therapeutic possibilities across a wide range of medical applications.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Workit Health provides online therapeutic content and professional counseling services for substance use recovery. It offers Workit, an interactive platform for individuals seeking to reduce or quit alcohol consumption, providing discreet access to on-demand medical and psychosocial support.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Braid Health, Inc. is a digital health innovation company founded in 2018 and based in San Francisco, California. It specializes in developing artificial intelligence-driven diagnostic tools specifically for radiology. By creating an AI-powered diagnostic collaboration platform, Braid Health enhances the speed, quality, and workflow of radiologists and healthcare providers. The company’s systems integrate AI diagnostics with the expertise of board-certified radiologists, facilitating real-time quality assurance and seamless Electronic Health Records (EHR) integration. This approach enables healthcare professionals to deliver accurate diagnoses efficiently, ultimately improving the quality of patient care.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

AllStripes is a healthcare technology company focused on accelerating the development of new treatments for rare diseases. The company has created a platform that enables the generation of regulatory-ready evidence, facilitating rare disease research and drug development. AllStripes operates a two-sided network that connects patients with rare diseases and advocacy groups to life science companies seeking new drug candidates. Through this network, patients can contribute their medical data and participate in treatment research online, while life science companies gain access to valuable data and insights to support their drug development efforts.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

HumanFirst is a company focused on enhancing patient-centered clinical trials through its advanced precision measures platform, which is recognized as the world's largest AI-powered software-as-a-service solution for improving health outcomes. The platform offers insights and validated evidence data to support biopharmaceutical companies in their drug development processes, enabling them to incorporate digital health technologies, digital biomarkers, and electronic clinical outcome assessments. By providing industry educational tools and facilitating collaboration with research partners, HumanFirst helps biopharma organizations increase research efficiency and accelerate the deployment of innovative treatments. The platform has been utilized by a significant majority of the largest pharmaceutical companies globally, underscoring its role in transforming clinical research and driving the evolution of drug development.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Variant Bio Inc. is a biotechnology company focused on developing therapeutics through the exploration of human genetic diversity. Founded in 2018 and headquartered in Seattle, Washington, the company seeks to identify individuals and populations exhibiting extreme outlier traits relevant to various medical conditions. By employing advanced sequencing technologies, statistical genetics, and machine learning, Variant Bio analyzes the genetic underpinnings of these traits to uncover new therapeutic targets. The company's mission is to enhance global health by addressing unmet medical needs, particularly in areas such as neurodegenerative, autoimmune, and cardiometabolic diseases.

Workit Health provides online therapeutic content and professional counseling services for substance use recovery. It offers Workit, an interactive platform for individuals seeking to reduce or quit alcohol consumption, providing discreet access to on-demand medical and psychosocial support.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.

Visla Labs Inc. is a San Francisco-based company established in 2018 that focuses on developing an artificial intelligence platform tailored for the radiology and healthcare sectors. The company aims to innovate and enhance healthcare delivery through advanced AI technologies, positioning itself as a key player in the evolving landscape of medical diagnostics and patient care. With venture capital support, Visla Labs is poised for significant growth and is working towards achieving critical milestones in its development.

Braid Health, Inc. is a digital health innovation company founded in 2018 and based in San Francisco, California. It specializes in developing artificial intelligence-driven diagnostic tools specifically for radiology. By creating an AI-powered diagnostic collaboration platform, Braid Health enhances the speed, quality, and workflow of radiologists and healthcare providers. The company’s systems integrate AI diagnostics with the expertise of board-certified radiologists, facilitating real-time quality assurance and seamless Electronic Health Records (EHR) integration. This approach enables healthcare professionals to deliver accurate diagnoses efficiently, ultimately improving the quality of patient care.

AllStripes is a healthcare technology company focused on accelerating the development of new treatments for rare diseases. The company has created a platform that enables the generation of regulatory-ready evidence, facilitating rare disease research and drug development. AllStripes operates a two-sided network that connects patients with rare diseases and advocacy groups to life science companies seeking new drug candidates. Through this network, patients can contribute their medical data and participate in treatment research online, while life science companies gain access to valuable data and insights to support their drug development efforts.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Halo Neuro, established in 2013 and headquartered in San Francisco, specializes in developing neurotechnology systems. Its flagship product, Halo Sport, employs a technique called Neuropriming, which combines electrical stimulation with movement-based training to enhance skill and strength acquisition in elite athletes. This process temporarily boosts the brain's learning capacity, or 'hyperplasticity', refining its ability to adapt to training. The company aims to help individuals unlock their full potential through innovative brain stimulation technology.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Physera, Inc. is a healthcare company focused on providing digital solutions for patients with musculoskeletal injuries. Founded in 2015 and based in Palo Alto, California, Physera offers a mobile application that connects patients to licensed physical therapists for remote diagnosis and treatment. The platform features video access to therapists, as well as in-app animations, voice prompts, and digital exercise therapy designed to alleviate musculoskeletal pain. By collecting data on patient progress and treatment effectiveness, the application allows therapists to tailor recovery and maintenance plans to individual needs. Physera serves a diverse clientele that includes patients suffering from muscular pain, self-insured employers, and large health plans. As of May 2020, Physera operates as a subsidiary of Omada Health, Inc.

Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Workit Health provides online therapeutic content and professional counseling services for substance use recovery. It offers Workit, an interactive platform for individuals seeking to reduce or quit alcohol consumption, providing discreet access to on-demand medical and psychosocial support.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Halo Neuro, established in 2013 and headquartered in San Francisco, specializes in developing neurotechnology systems. Its flagship product, Halo Sport, employs a technique called Neuropriming, which combines electrical stimulation with movement-based training to enhance skill and strength acquisition in elite athletes. This process temporarily boosts the brain's learning capacity, or 'hyperplasticity', refining its ability to adapt to training. The company aims to help individuals unlock their full potential through innovative brain stimulation technology.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Capella BioScience is engaged in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAbs targeting oncology, autoimmune diseases, and other medical conditions. Capella BioScience collaborates with biotechnology firms and academic institutions to enhance its research and development efforts, aiming to advance innovative therapeutic solutions in the medical field.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Halo Neuro, established in 2013 and headquartered in San Francisco, specializes in developing neurotechnology systems. Its flagship product, Halo Sport, employs a technique called Neuropriming, which combines electrical stimulation with movement-based training to enhance skill and strength acquisition in elite athletes. This process temporarily boosts the brain's learning capacity, or 'hyperplasticity', refining its ability to adapt to training. The company aims to help individuals unlock their full potential through innovative brain stimulation technology.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.

Kereos, Inc. is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of nanoscale drug delivery technologies and molecular imaging agents aimed at the detection and treatment of cancer and cardiovascular diseases. Founded in 1999, Kereos focuses on targeted delivery systems that enhance the effectiveness of therapeutic compounds, including existing drugs and novel candidates, particularly those that are too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001 and KER-1002, both cancer therapeutics utilizing natural products with demonstrated anti-tumor efficacy, and KER-1003, which targets angiogenesis. Additionally, Kereos offers diagnostic applications, such as KER 0001, an imaging platform for detecting angiogenesis. The company is also engaged in developing partnerships with pharmaceutical and imaging firms to advance its molecular imaging systems and cardiovascular disease MRI agents, thereby broadening its impact in the healthcare sector.

mPharma is a healthcare company focused on enhancing access to affordable medications in emerging markets. Founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with drug manufacturers, insurance providers, financial institutions, and governments to streamline the delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory, prescribing medications, and reporting adverse drug reactions. By ensuring that high-quality chronic disease medications are consistently available at sustainable prices, mPharma aims to improve health outcomes for patients, doctors, and pharmacists alike.